Onkológia 3/2024

HIF inhibitors and glutaminase inhibitors in the treatment of advanced renal cell carcinoma

Currently, treatment options for patients with metastatic renal cell carcinoma (mRCC) are limited to immunotherapy with checkpoint inhibitors and targeted therapy that inhibits vascular endothelial growth factor receptors (VEFG-R) and mammalian target of rapamycin (mTOR). Despite the greatly improved outcomes seen over the past decades, the majority of mRCC patients eventually develop resistance to given modalities, highlighting the critical need for new treatment options. Recent research has shown that ccRCC is a metabolic disease. Metabolic alterations are responsible new potential targets for treatment, and the article provides an overview of targeting drugs hypoxia-inducible factor 2α (HIF-2α) and glutaminase (GL).

Keywords: metabolism, HIF, HIF inhibitor, hypoxia-inducible factor 2α, VEGF, VHL, glutaminase inhibitors